Ivonescimab combined with hypofractionated stereotactic reirradiation for recurrent WHO grade 4 glioma: protocol for a single-arm phase II trial
Background Recurrent WHO grade 4 glioma remains a major therapeutic challenge, with limited durable benefit from currently available salvage treatments. Although immune checkpoint blockade alone has shown limited activity in glioblastoma, hypofractionated stereotactic reirradiation (re-HFSRT) may promote tumor antigen release, immunogenic cell death, and local immune priming. Ivonescimab, a bispecific antibody targeting PD-1 and VEGF-A, may simultaneously enhance antitumor T-cell activity and attenuate VEGF-driven vascular and immune suppression. Methods This investigator-initiated, prospective, single-center, open-label, single-arm phase II trial will evaluate ivonescimab combined with HFSRT in adults aged 18–75 years with histologically confirmed recurrent WHO grade 4 glioma and at least one measurable lesion. The planned sample size is 21 patients. Enrolled patients will receive ivonescimab 10 mg/kg intravenously every 3 weeks, with HFSRT initiated at the first dose and delivered as 30 Gy in 5 fractions every other day. Ivonescimab will be continued until disease progression, unacceptable toxicity, withdrawal of consent, investigator-assessed absence of clinical benefit, or completion of 2 years of treatment, whichever occurs first. Contrast-enhanced MRI will be performed at baseline, at 3 weeks after the first study treatment for early safety assessment and evaluation of early radiological changes, and every 8 weeks thereafter during treatment. The primary endpoint is progression-free survival (PFS). Secondary endpoints include objective response rate (ORR), disease control rate (DCR), overall survival (OS), treatment-related adverse events, and health-related quality of life. Exploratory analyses will assess selected biomarkers, including PD-L1 expression, MGMT promoter methylation, tumor mutational burden (TMB), and microsatellite status, when available. Discussion This study will provide preliminary evidence on the efficacy and safety of ivonescimab combined with hypofractionated stereotactic reirradiation in recurrent WHO grade 4 glioma and inform future controlled studies. The single-arm design precludes determination of the contribution of each treatment component or confirmation of synergistic effects. Clinical trial registration https://www.chictr.org.cn , identifier ChiCTR2600122533.
Authors
- Ming Fan (ORCID: https://orcid.org/0000-0001-8676-2716)
- Xin Lai (ORCID: https://orcid.org/0000-0002-2565-1833)
- Jingsong Liu
- Shuo Zhang (ORCID: https://orcid.org/0000-0003-1120-5872)
- Peng Xu (ORCID: https://orcid.org/0000-0002-8284-5730)
- Yue Zhao
- Jun Yin
- Ke Xu
- Jie Zhou
- Xiaohan Zhou
- Yecai Huang
- Shichuan Zhang
Institutions
- University of Electronic Science and Technology of China (CN)
- Sichuan Cancer Hospital (CN)
- Sichuan Nursing Vocational College (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-11-20
- DOI
- https://doi.org/10.3389/fimmu.2026.2002089
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00